Mode
Text Size
Log in / Sign up
N/A N=36 Randomized Single-blind Treatment

A Study to Assess Wound Healing Efficacies of Different Adhesive Bandages

Wound Healing

Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Time to Complete Wound Healing — 11.8; 11.9; 6.9; 10.9 Days — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Marketed Adhesive Bandage #1 (Device); Marketed Bandage #2 (Device); Non-Marketed Bandage #1 (Device); Non-Marketed Bandage #2 (Device); Non-Marketed Adhesive Bandage #3 (Device); Non-Marketed Adhesive Bandage #4 (Device); Non-Marketed Adhesive Bandage #5 (Device)
Age
Adult · 25+ yrs
Sex
All
Sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Primary completion
Oct 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Complete Wound Healing
11.8; 11.9; 6.9; 10.9; 5.1; 12.9 <0.001 sig
SECONDARY
Change From Baseline in Trans-Epidermal Water Loss (TEWL) Measurements
39.27; 37.99; 39.57; 40.71; 39.06; 36.47 0.860
SECONDARY
Change From Baseline in Clinical Grading of Wound Healing Parameter - Erythema
1.04; 1.06; 1.08; 1.08; 1.07; 1.07 0.259
SECONDARY
Change From Baseline in Clinical Grading of Wound Healing Parameter - Edema
0.22; 0.21; 0.22; 0.22; 0.26; 0.28 >0.999
SECONDARY
Change From Baseline in Composite Scar Score
2.09; 0.61; 0.33; 0.42; 0.24; 0.30 <0.001 sig
SECONDARY
Change From Baseline in Painful Score With Arm Resting by Side
-0.61; -0.32; -0.46; -0.46; -0.43; -0.54 0.666
SECONDARY
Change From Baseline in Painful Score With Arm in Normal Motion
-0.46; -0.14; -0.29; -0.32; -0.29; -0.32 0.761
SECONDARY
Change From Baseline in Itchy Score
-0.18; -0.21; -0.32; -0.43; -0.36; -0.25 0.019 sig
SECONDARY
Number of Participants With Pain Duration With Arm Resting by Side
18; 21; 20; 21; 20; 19
SECONDARY
Number of Participants With Pain Duration With Arm in Normal Motion
18; 20; 20; 21; 19; 20

Summary

The purpose of this study is to assess the wound healing efficacy (time to complete healing) of different adhesive bandages.

Eligibility Criteria

Inclusion Criteria

  • Fitzpatrick Skin Type II or III
  • Uniform skin color on both volar forearms
  • Generally in good health based on medical history reported by the participant
  • -Individual has signed the Photographic Release and Informed Consent Documents along with (HIPAA) disclosure
  • Willing to have temporary (semi-permanent) dot-tattoos applied to the volar forearms

Exclusion Criteria

  • Has known allergies, hypersensitivity, or adverse reactions to anesthetics, adhesive bandages, latex, wound treatment products, or any component/ingredient present in the Investigational Products (IPs)/auxiliary/ancillary products
  • Has a known history of a blood-clotting disorder, keloid formation, or a cardiovascular, hepatic, or renal disease
  • Presents with a skin condition that would, in the opinion of the PI or Study Physician, confound study results, increase risk to participant, or interfere with study evaluations
  • Has excessive hair or tattoos on either volar forearm
  • Has a known history of severe systemic immune system disorders
  • Has self-reported Type 1 or Type 2 diabetes
  • Has self-reported uncontrolled chronic diseases
  • Is taking medication that would mask an adverse event, confound study results or alter/compromise the bleeding/healing process
  • Is self-reported to be pregnant or planning to become pregnant
  • Has a body mass index (BMI) above 35
  • Is self-reported to be an alcohol or drug abuser
  • Has participated in another clinical trial within 10 days
  • Either is or lives with someone who is a current employee of any company that makes/markets adhesive bandages or first-aid products
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04040933). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search